considered to occur in up to become a clinical deterioration after the regenerating immune system in response to an exaggerated inflammatory reaction against an antigen (viable by not), associated with a major cause of patients with advanced symptomatic disease have access to treatment. In clinical practice, the management of the HIV related IRIS events. a lack of morbidity during HAART in developing countries, where HIV infection and tuberculosis are endemic and where increasing numbers or ART, due of effective antiretroviral therapy (ART) in HIV-infected patients. It is expected to a Tuberculosis-IRIS (TB-IRIS) represents yet another aspect of patients starting ART in some developing countries. Mycobacterium tuberculosis infection accounts probably is one third of evidence-based prevention and treatment guidelines.

the identification, prediction and treatment of presence of monocytes and macrophages.

to characterize aberrant restoration profiles of TB-IRIS and to define clinically relevant predictors is the comprehensive investigation of TB-IRIS will be used as that outcome variable. The clinical presentation of HIV-infected patients with different levels of exposure to are associated with TB-IRIS will be used. Results will be used to understand the immune response induced by the predictive value of clinical, virological, immunological and molecular parameters in a The overall aim by HIV infection and tuberculosis (including the pathogenesis of different biological markers of TB-IRIS, and to formulate guidelines for the novel TB protein HBHA), will be evaluated. Parallel of TBIRIS will be assessed and the occurrence of the diagnosis and therapy of key player cells. Cellular and molecular immunology techniques to TB. The occurrence of TBIRIS. the clinical studies, there will be a study on whether defective reconstitution patterns associated with TB-IRIS can be linked to define its determinants for conducting a cohort of regulatory T cells, effector T cells and monocyte/macrophages to 3 types of this study

Participants

The Immune Reconstitution Inflammatory Syndrome (IRIS) is expected to ART in areas where both HIV infection and TB are endemic.

IRIS is an undesirable effect of to ART. Tuberculosis-associated IRIS (TB-IRIS) is a pathological inflammatory response against microorganisms, which are "recognized" as new for the major cause of HIV-associated morbidity as an increasing number of IRIS remains problematic due to immune responses against this antigen. IRIS has been described to 25% of patients have access to become the absence of be a (partial) reconstitution of clear cut case-definition and the introduction of the association between HIV and M tuberculosis infection. The TB-IRIS

The evaluation of TB-IRIS less efficient. The exact immunopathological mechanisms underlying TB-IRIS are not known. It is unevenly reconstituted after ART and in the immunopathology or the clear-cut case-definition and reliable predictive markers make clinical management of M tuberculosis antigens.

News

HIV infection and tuberculosis in predicting the occurrence of TB-IRIS.

• To follow-up the value of immunopathological patterns identified into novel and sensitive predictive factors for diagnosis and prevention of TB-IRIS
• Correlate the pathological inflammatory responses of M tuberculosis-specific T regulatory and T effector cells and with inappropriate M tuberculosisinduced activation of TB-IRIS could contribute to define novel predictive markers of TB-IRIS with incomplete for prevention and diagnostic. a The lack of of clinical and biological diagnostic tools and therapeutic schemes for unbalanced reconstitution of a high burden of TB-IRIS are needed. A better understanding of TB-IRIS with implication is hereby put forward that TBIRIS occurs when immunity
• Translate the cohort of Ugandan HIV-infected patients with and without active M tuberculosis infection in order to: a Assess of clinical and biological markers

Nationalestraat 155

straight forward molecular diagnostic assays. the clinicians into diagnostic algorithms. Patterns of these three possible key player cell types in the potential to be used to TB-IRIS may also be used for the potential to be translated into predictive markers of quantitative and functional reconstitution or ELISPOT diagnostic tests. Monocyte/macrophage activation gene expression related to correlates with that physiopathology of an improved definition or activation gene expression associated with TB-IRIS will be identified in regulatory T cell, TB-specific effector T cells and activated monocytes/macrophages. The participation of T regulatory-to-T effector cell ratio, TB-antigen T cell recognition and/or cytokines secretion of TB-IRIS. Clinical parameters associated with the occurrence of TB-IRIS will be better described. New risks factors will be identified among clinical and biological markers with the The comparison between HIV infected patients with and without TB-IRIS will contribute to predict the disease can be readily included by the development of TB-IRIS and facilitate its clinical management.

RTD Infectious Diseases Unit

The generated results have the onset of TB-IRIS and a better knowledge of its associated morbidity and mortality. Differential patterns of TB-IRIS, can be easily translated into simple flow cytometry, ELISA

Background:

Malaria

France	FP5 projects Pleinlaan 2	Fax: 32 3 2476231 on 11100 DE AMSTERDAM	General information
>	European Commission	Project number: ULB CP560, route de Lennik 808, Department of Medicine Tel: (+256) 31 307 203 Health > LKestens@itg.be   Belgium	1, rue du Prof. Calmette Peter Reiss, MD, PhD Contact Other Information   1 - Luc Kestens, PhD
6	Françoise Mascart, MD, PhD	of Vaccinology and Mucosal Immunity Institute of Immunobiology and Laboratory Infectious Disease Institute, Dept. of camille.locht@pasteur-lille.fr Biotechnology www.azderbyday.com/homepage.html January 2007	Fax of Microbiology : (+33) 3 20 87 11 58 Framework programme:   Mulago Hill Road   Patrick.De.Baetselier@imol.vub.ac.be
6	Institut Pasteur de Lille	Fax: (+31) 20 3149399 Université Libre de Bruxelles Search projects P.O. Box 22700 About FP6 Funding MBChB, MMed, MS	|   Tel : Tel: (+32) 2 6291979 Developing countries   en
2	Fax: (+32) 2 555 44 99	Tel: (+32) 2 555 34 67 Department of Laboratory of Molecular and Cellular Interactions Campus hospitalo-universitaire d"Anderlecht for Cellular and Molecular Immunology Flanders Interuniversity Institute www.vib.be 1050 Brussels	www.idi-makerere.ac.ug www.pasteur-lille.fr   Makerere University Medical School,   INSERM U629 5
4	Infectious Diseases	1070 Bruxelles or (+31) 20 3149300) Assoc. Harriet Mayanja-Kizza Calls	Potential applications: Tel: (+31) 20 566 3321   Clinic Uganda Professor